Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3143921 Hydrate in Advanced Solid Tumours
NCT03096054Phase 1Completed
- Sponsor
- Cancer Research UK
- Start
- Jun 2017
- Primary completion
- Apr 2025
- Countries
- 1
01
Overview
Phase 1, open-label trial of LY3143921 in colorectal cancer (CRC), ovarian cancer, non-small cell lung cancer (NSCLC) and 5 more (2 arms), sponsored by Cancer Research UK. Primary endpoints: Maximum Tolerated Dose at 28 days and Adverse Events. Started Jun 2017; status: completed.
02
Drugs
LY3143921
03
Conditions
colorectal cancer (CRC)ovarian cancernon-small cell lung cancer (NSCLC)esophageal cancerhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03096054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03096054.